Abstract: A system for monitoring pressure within a volume defined by a wall has a housing and a manometer coupled to the housing having fluid therein. The manometer is coupled to the volume and has a fluid level corresponding to a pressure within the volume. A pressure sensor is coupled to the housing and is coupled to volume. The pressure sensor generates a pressure signal corresponding to the pressure within the volume. A controller is coupled to the pressure sensor and is programmed to compare the pressure signal to a threshold and programmed to generate an indicator based on comparing.

Abstract: A bag sealing system for securing one or more items in a closable bag comprises a moveable frame, a closable bag, a closing device and a driving device. The moveable frame can have an open configuration, intermediate configurations and a closed configuration. The closable bag has an open end and a closed end wherein the open end of the closable bag is coupled to the moveable frame. The closing device is provided for securely closing the open end of the bag via a securing element, and the driving device is coupled to the closing device to actuate the closing device to securely close the closable bag.

Abstract: A method and system for monitoring using a sub-slab sensor assembly for a building having a slab includes a housing, a first air quality sensor coupled to the housing and generating a first air quality signal for air above the slab, a second air quality sensor coupled to the housing and generating a second air quality signal for air below the slab and a pressure sensor coupled to the housing. The pressure sensor generates a pressure signal corresponding to the pressure below the slab. A position sensor generates a position signal corresponding to a location of the sensor. A network interface communicates the first air quality signal, the second air quality signal or the pressure signal, or warning signals corresponding thereto and the position signal to a network.

Abstract: A bag sealing system for securing one or more items in a closable bag comprises a moveable frame, a closable bag, a closing device and a driving device. The moveable frame can have an open configuration, intermediate configurations and a closed configuration. The closable bag has an open end and a closed end wherein the open end of the closable bag is coupled to the moveable frame. The closing device is provided for securely closing the open end of the bag via a securing element, and the driving device is coupled to the closing device to actuate the closing device to securely close the closable bag.

Abstract: A system for monitoring pressure within a volume defined by a wall has a housing and a manometer coupled to the housing having fluid therein. The manometer is coupled to the volume and has a fluid level corresponding to a pressure within the volume. A pressure sensor is coupled to the housing and is coupled to volume. The pressure sensor generates a pressure signal corresponding to the pressure within the volume. A controller is coupled to the pressure sensor and is programmed to compare the pressure signal to a threshold and programmed to generate an indicator based on comparing.

Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.

Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.

Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.

Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.